23.94
0.75 (3.23%)
| Penutupan Terdahulu | 23.19 |
| Buka | 23.25 |
| Jumlah Dagangan | 50,122 |
| Purata Dagangan (3B) | 1,350,329 |
| Modal Pasaran | 1,780,020,480 |
| Harga / Jualan (P/S) | 17.33 |
| Harga / Buku (P/B) | 3.58 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2026 |
| Margin Keuntungan | -163.17% |
| Margin Operasi (TTM) | -131.93% |
| EPS Cair (TTM) | -3.04 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 104.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 34.73% |
| Nisbah Semasa (MRQ) | 5.89 |
| Aliran Tunai Operasi (OCF TTM) | -161.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -84.53 M |
| Pulangan Atas Aset (ROA TTM) | -11.42% |
| Pulangan Atas Ekuiti (ROE TTM) | -34.05% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Xencor, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | -1.67 |
|
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.24% |
| % Dimiliki oleh Institusi | 111.90% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |